Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.

Date
2021
Author
AKOVA, MURAT
Erdinc, Fatma Sebnem
AKALIN, EMİN HALİS
TABAK, Ömer Fehmi
PULLUKÇU, HÜSNÜ
Batum, Ozgur
TURHAN, ÖZGE
Yildirmak, Mustafa Taner
KÖKSAL, IFTAHAR
DURUSU TANRIÖVER, MİNE
Doganay, Hamdi Levent
Kose, Sukran
Guner, Hatice Rahmet
Azap, Alpay
AKHAN, SILA
TAŞOVA, YEŞİM
KORTEN, VOLKAN
YILMAZ, GÜRDAL
ÇELEN, MUSTAFA KEMAL
Altin, Sedat
Celik, Ilhami
BAYINDIR, YAŞAR
Karaoglan, Ilkay
Yilmaz, Aydin
ÖZKUL, AYKUT
Gur, Hazal
ÜNAL, SERHAT
Yavuz, Serap Simsek
Metadata
Show full item record
Abstract
Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.
URI
http://hdl.handle.net/20.500.12627/172739
https://doi.org/10.1016/s0140-6736(21)01429-x
Collections